Related Experiment Video
Updated: Jun 8, 2026

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Hepatitis B reactivation and current clinical impact
B Alvarez-Suárez1, J de-la-Revilla-Negro, B Ruiz-Antorán
1Servicio de Gastroenterología y Hepatología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Universidad Autónoma de Madrid, Spain.
Abstract:
Hepatitis B virus (HBV) reactivation results from increased viral replication in inactive carriers or patients with prior infection with HBV. Reactivation may occur spontaneously or secondary to immunomodulating or immunosuppressive chemotherapy. Reactivation may manifest with no symptoms but on occasion results in acute or even severe acute hepatitis. Prevention is the best management approach, hence HBV screening using serology should be performed for all patients undergoing any immunomodulating, immunosuppressive or chemotherapeutic treatment. Antiviral prophylaxis has proven effective in inactive carriers and in some patients with former infection with HBV undergoing selected immunosuppressive therapies.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Acute Pancreatitis II: Clinical Manifestations and Management
Chickenpox
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Inhibitors of Viral Protein Synthesis

